Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Veracyte Inc. (VCYT)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 2,295,951 | $134,841,222 | -25% | 0.88% |
| 2. | Driehaus Capital Richard Driehaus | 1,045,826 | $61,421,361 | 0.36% | |
| 3. | Point72 Asset Management Steve Cohen | 737,804 | $43,331,229 | +53% | 0.05% |
| 4. | Fisher Asset Management Ken Fisher | 700,592 | $41,145,767 | -5% | 0.01% |
| 5. | BAMCO Inc. Ron Baron | 650,686 | $38,214,789 | -1% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.33 | 60,000 | $980,094.00 | 159,761 | 2022-06-10 | Filing | |
| $35.19 | 2,000 | $70,389.20 | 2,000 | 2021-06-03 | Filing | |
| $5.32 | 2,500 | $13,288.00 | 10,000 | 2016-06-03 | Filing | |
| $5.48 | 2,500 | $13,693.25 | 7,500 | 2016-06-02 | Filing | |
| $5.46 | 2,500 | $13,641.75 | 5,000 | 2016-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 4,015 | $160,600.00 | 124,329 | 2026-09-21 | Filing | |
| $40.95 | 5,000 | $204,747.00 | 27,471 | 2026-09-14 | Filing | |
| $43.66 | 2,705 | $118,105.17 | 133,048 | 2026-09-04 | Filing | |
| $42.89 | 10,405 | $446,304.79 | 135,753 | 2026-09-04 | Filing | |
| $43.71 | 1,175 | $51,363.95 | 166,025 | 2026-09-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,486,437 | $792,058,442 | 0.01% | |
| 2. | 7,702,746 | $452,382,262 | 0.02% | |
| 3. | 5,538,404 | $325,270,469 | 0.52% | |
| 4. | 4,716,191 | $276,981,897 | 0.01% | |
| 5. | 4,698,128 | $275,953,046 | 0.01% |
News See All
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S.
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript May 5, 2026Veracyte, Inc. beats earnings expectations. Reported EPS is $0.52, expectations were $0.34.
Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript February 25, 2026Veracyte, Inc. beats earnings expectations. Reported EPS is $0.53, expectations were $0.4083.
Does Veracyte (VCYT) Offer Both Strength and Opportunity?
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”.
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
In this article, we will take a look at the 13 Best Innovative Stocks to Buy According to Wall Street Analysts. Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating
We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Veracyte, Inc. is one of the high growth stocks on our list.
15 High Growth Mid-Cap Stocks to Buy
In this article, we will be taking a look at the 15 High Growth Mid-cap Stocks to Buy.
Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)
Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In. The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc.
Hedge Fund Resource Center